University College Cardiff Consultants Limited

Array Biopharma Inc.

Other

Astrazeneca Ab

Asrtazeneca Ab

Cardiff Scintigraphics Limited

Paul Alfred Dickinson

John A DeMattei

James Gair Ford

Ronald John Roberts

Christopher John Squire

Mohammed Pervez

Tsung-Hsun Chuang

Richard Anthony Storey

Gorkhn Sharma-Singh

Peter Ghazal

Simon John Warren

Ben Stenson

Thorsten Forster

Mizan Khondoker

Claire Smith

Ian Walter Kellaway

Stephen Wyn Howells

John Demattei

Sepsis remains a leading cause of morbidity and mortality in neonates worldwide. There is also clinically a low threshold for suspicion of infection in neonates, in particular as presentation varies greatly from very subtle to catastrophic collapse. The lack of reliably sensitive tests and the potential life-threatening consequences of delayed treatment of infection results in the widespread use of empirical antibiotics exposing many infants without infection to broad-spectrum antibiotics. The present invention provides a series of patient-invariant biomarkers for screening neonates and other subjects for infection that predicts bacterial infection with high accuracy; and is further shown to have predictive value in identifying infection in suspected cases with blood-culture negative tests.

Molecular predictors of sepsis

The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation. 

Hydrogen sulfate salt

An aerosol composition comprising a propellant and a first particulate material comprising particles having a median aerodynamic diameter with the range 0.05 to 11 &#x3bc;m, such as a medicament suitable for pulmonary inhalation, and a second particulate material comprising particles having a median volume diameter within the range 15 to 200 &#x3bc;m. The presence of the second particulate material provides good suspension properties, particularly where the propellant is a hydrofluoro alkane.

Aerosol composition

Nanoparticles are prepared from a colloidal system comprising a continuous phase and micelles, the micelles comprising surfactant material. A microemulsion is formed by admixing the colloidal system with a solution of an active material, such as a medicament, dissolved in a solvent wherein the solution forms a disperse phase with the micelles of surfactant material. At least the dispersed phase is quenched to a solid state and the continuous phase and solvent are removed to produce the nanoparticles. The nanoparticles can be incorporated in an aerosol composition suitable for deep lung delivery by means of a metered dose inhaler.

Particulate composition

An aerosol composition comprising a propellant and a first particulate material comprising particle having a median aerodynamic diameter within the range 0.05 to 11 &mgr;m, such as a medicament suitable for pulmonary inhalation, and a second particulate material comprising particles having a median volume diameter within the range 15 to 200 &mgr;m. The presence of the second particulate material provides good suspension properties, particularly where the propellant is a hydrofluoro alkane.

Growing community of inventors

Macclesfield, United Kingdom

Paul Alfred Dickinson